RedHill Biopharma (RDHL) EBITDA Margin (2012 - 2023)

RedHill Biopharma (RDHL) has reported EBITDA Margin for 12 consecutive years, with 2992.87% the latest figure, recorded in Q2 2023.

• On a quarterly basis, EBITDA Margin rose 294295.0% year-over-year to 2992.87% in Q2 2023; TTM through Jun 2023 was 122.98%, a 797.0% increase from a year earlier, with the FY2025 full-year figure at 2776.92%, down 269642.0% from the prior year.
• EBITDA Margin was 2992.87% for Q2 2023 at RedHill Biopharma, up from 808.0% in the prior quarter.
• Over five years, EBITDA Margin peaked at 2992.87% in Q2 2023 and troughed at 808.0% in Q1 2023.
• A 5-year average of 336.14% and a median of 90.03% in 2020 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin slumped 152314 bps in 2021 and soared 294295 bps in 2023, its largest moves.
• Over 5 years, EBITDA Margin stood at 739.87% in 2019, then sank by 88 bps to 91.83% in 2020, then slumped by 798 bps to 641.43% in 2021, then gained by 8 bps to 591.81% in 2022, then surged by 606 bps to 2992.87% in 2023.
• The last three EBITDA Margin figures came in at 2992.87% (Q2 2023), 808.0% (Q1 2023), and 591.81% (Q4 2022), per Business Quant data.